TVAMP
LRMR icon

Tennessee Valley Asset Management Partners’s Larimar Therapeutics LRMR Stock Holding History

Tennessee Valley Asset Management Partners’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8
Closed -$36 – 466
2023
Q4 		$36 Buy
+8
New +$27 ﹤0.01% 814

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tennessee Valley Asset Management Partners's LRMR Position: Q1 2024 in Review

Tennessee Valley Asset Management Partners sold out of Larimar Therapeutics (LRMR) in Q1 2024, closing a stake of 8 shares — an estimated $36 sold.

Tennessee Valley Asset Management Partners first reported a position in LRMR in Q4 2023 and held it in 1 quarter. The position peaked at $36 in Q4 2023. 104 funds tracked by Wall St. Rank hold LRMR as of Q1 2024.

  • Tennessee Valley Asset Management Partners reported no remaining Larimar Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Tennessee Valley Asset Management Partners sold 8 Larimar Therapeutics shares in Q1 2024, an estimated $36.
  • Tennessee Valley Asset Management Partners first reported a position in Larimar Therapeutics in Q4 2023 and held it in 1 quarter.
  • Tennessee Valley Asset Management Partners's Larimar Therapeutics position peaked at $36 in Q4 2023.
  • 104 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2024.

Based on Tennessee Valley Asset Management Partners's 13F filing for Q1 2024, filed 23 Apr 2024.